Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 4,285 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard Heyman sold 4,285 shares of the business’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $25.00, for a total value of $107,125.00. Following the completion of the sale, the director directly owned 25,107 shares of the company’s stock, valued at approximately $627,675. This trade represents a 14.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Enliven Therapeutics Stock Performance

ELVN stock traded down $0.97 during trading on Monday, hitting $25.03. 1,373,161 shares of the company traded hands, compared to its average volume of 2,697,186. The company has a 50-day moving average of $19.07 and a 200-day moving average of $19.95. Enliven Therapeutics, Inc. has a 1 year low of $13.30 and a 1 year high of $29.98. The firm has a market capitalization of $1.49 billion, a PE ratio of -13.60 and a beta of 0.41.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.11. Sell-side analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Hedge Funds Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ELVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Enliven Therapeutics by 8.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after buying an additional 1,693 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Enliven Therapeutics by 61.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock valued at $4,167,000 after acquiring an additional 80,506 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $578,000. Rhumbline Advisers raised its position in shares of Enliven Therapeutics by 4.9% in the 1st quarter. Rhumbline Advisers now owns 52,502 shares of the company’s stock worth $1,033,000 after acquiring an additional 2,466 shares in the last quarter. Finally, KLP Kapitalforvaltning AS raised its position in shares of Enliven Therapeutics by 58.1% in the 2nd quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock worth $136,000 after acquiring an additional 2,500 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.